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Palivizumab (PZ) is the only monoclonal antibody in human use against an infectious disease. PZ is a humanized monoclonal antibody
that recognizes the fusion protein of respiratory syncytial virus (RSV). PZ prophylaxis reduces the likelihood of hospitalization for young
children at risk for severe RSV infections. The quasispecies nature of RNA viruses allows rapid emergence of viruses with a selective
advantage. A PZ resistant virus was selected by passage of RSV in the presence of PZ in cell culture. The cell culture-derived virus was
completely resistant to PZ prophylaxis in cotton rats. The increasing use of PZ, and in particular, the use of PZ in immunosuppressed patients,
provide opportunities for resistant viruses to emerge. Whether such viruses will appear and be of clinical significance for humans is unknown.
Preclinical studies in cotton rats predicted the efficacy of PZ in humans; these results suggest that if PZ resistant viruses arise in humans, PZ
prophylaxis may be ineffective.
D 2003 Elsevier Inc. All rights reserved.Keywords: Virus; Mutant; PalivizumabIntroduction
Infants born prematurely and those with chronic lung
disease are at risk for severe disease due to respiratory
syncytial virus (RSV) infection. A humanized monoclonal
antibody [palivizumab (PZ)] neutralizes RSV through
interaction with the RSV F glycoprotein. PZ monthly
injections for the 5 months spanning the annual RSV
epidemic period reduce the risk of hospitalization among
high-risk children (IMPACT, 1998). RSV also causes
severe respiratory illness in immunocompromised individ-
uals such as stem cell transplant (SCT) recipients. PZ has
been administered to SCT patients (Boeckh et al., 2001).
Over 400000 patients have received PZ and use continues
to increase (Product Insert, 2002). For example, PZ has
recently received Food and Drug Administration approval
for prophylactic use in children with hemodynamically
significant congenital heart disease.0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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emergence of viruses with a selective advantage (Domingo
and Holland, 1994). Antibody selection of variant RSV in
cell culture is well described, including mutant selection
by the murine parent of PZ (Beeler and Van Wyke
Coelingh, 1989). Increasing PZ use in high-risk children
and in immunocompromised patients provides opportuni-
ties for PZ resistant viruses to arise and be transmitted
among humans. The goal of this study was to determine
whether a virus that resisted PZ in cell culture would also
resist prophylaxis in vivo. If a mutant virus were shown to
resist PZ prophylaxis in cotton rats, this would suggest that
PZ prophylaxis would be ineffective against similar
mutants in humans.Results
Selection of escape mutant
RSVA2 strain virus was propagated in HEp-2 cells in the
presence of increasing concentrations of PZ from 0.04 to 40
Ag/ml for five passages. By pass 5 in 40 Ag/ml PZ, there was
abundant viral CPE; this was designated resistant to PZ
Fig. 2. Growth kinetics of A2 and MP4 viruses. HEp-2 cells were split into
a 6-well plate the day prior to inoculation and infected with 2.5  105 PFU
of either A2 or MP4 viruses. At daily intervals, the virus-containing media
were harvested, stored at  70 jC, and titrated on Vero cells. Growth
capacity was expressed as the log value of plaque forming units per
milliliter.
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subjects is 40 Ag/ml (IMPACT, 1998). A single plaque pick
from pass 5 was designated MP4. The resistance of MP4 to
PZ was confirmed by microneutralization (Fig. 1). A2 virus
revealed dramatic reduction in replication at PZ concen-
trations of 4 and 40 Ag/ml, whereas the MP4 virus continued
to replicate.
Nucleotide and amino acid changes
Nucleotide sequence analysis revealed a nucleotide
change at F gene base 828 from A to T as compared to
the parent A2 virus. This resulted in a deduced amino acid
change in the F1 subunit at position 272 from Lys to Met.
The murine parent MAb 1129 selected for a variant with an
amino acid change at position 275 from Ser to Phe (Beeler
and Van Wyke Coelingh, 1989; Crowe et al., 1998). The
parent A2 virus F gene analysis revealed an ambiguity (G/T)
at position 1591. F gene position 1591 is G in the published
A2 and was T in the MP4 sequence (Collins et al., 1984). If
the parent sequence gene nucleotide were T, there would be
no coding change in MP4, if G, there would be an amino
acid change at residue 526 from Met to Ile. The parent A2
virus was susceptible to PZ, suggesting that the nucleotide
at position 1591 does not determine the resistance profile of
the parent A2 or of the MP4 virus.
Replication of MP4 in HEp-2 cells
The growth kinetics of the MP4 and A2 viruses were
compared. Both the A2 and MP4 viruses grew to nearly
identical levels, with peak titers exceeding 107 PFU/ml
during the third and fourth day after inoculation (Fig. 2).
Thus, as measured by production of infectious progeny, the
replication fitness of MP4 in HEp-2 cells was normal. This
suggested that the fusion protein was able to support cell
entry via fusion as an early step required for replication. TheFig. 1. Neutralization of A2 and MP4 viruses. Microneutralization was
performed as described (Anderson et al., 1985) to evaluate the resistance of
the A2 and MP4 viruses to neutralization of PZ. PZ concentrations are
shown in Ag/ml (X-axis) and mean absorbance (optical density) ( Y-axis).presence of syncytia in HEp-2 cells infected with MP4 also
indicated that fusion function was present.
Immunoblot reactivity of MP4 F protein
Immunoblot reactivity was assessed for the F proteins of
the A2 and MP4 viruses. The F proteins expressed by A2
and MP4 in infected cell lysates were indistinguishable with
primary antibody detection by the F protein MAb A8 (Fig.
3A) (MAb generously provided by Ed Walsh, Rochester,
NY) (Walsh et al., 1986). Detection with PZ showed
reactivity with the A2 but not the MP4 F1 protein (Fig.
3B). PZ detection of the A2 sample also revealed reactivity
with a protein that migrated faster than the F1 subunit; this
may be an F1 degradation product (Lopez et al., 1990).Fig. 3. Immunoblot detection of F proteins. Proteins in infected and mock
uninfected cell lysates were separated by SDS-PAGE and transferred to
PVDF membranes. Peroxidase-conjugated secondary antibodies were
detected by chemiluminescence. (A) F protein MAb A8 primary antibody
(1:20000), goat anti-mouse peroxidase-conjugated IgG secondary antibody
(1:20000); lanes 1: A2, 2: MP4, 3: Mock. (B) Palivizumab primary
antibody (1:10000), goat anti-human peroxidase-conjugated IgG secondary
antibody (1:20000); lanes 1: A2, 2: MP4, 3: Mock.
Table 1
Prophylaxis with palivizumab in cotton rats
Group (n) Prophylaxis Challenge virus Lung viral titer
(log, mean F SD)
A (9) PZ A2 1.7 F 0.1
B (12) PBS A2 4.2 F 0.5*
C (7) PZ MP4 5.2 F 0.5
D (7) PBS MP4 5.4 F 0.1
Data combined from two studies. Eight of nine group A animals had no
virus detected in the lungs. Group B (PBS control, A2 challenge) had three
animals with no virus recovered from the lungs, this control group should
uniformly yield virus and thus animals with no virus likely reflected failed
inoculations. Samples with no virus recovered from the lungs were assigned
a log value of 1.7 based on the lowest detectable measure of 1 plaque in
both wells at a 1:10 dilution.
*Student’s t test P value < 0.01 as compared to Group A.
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with PZ. In addition, the identical mobility of the F1
subunits of both A2 and MP4 indicated that cleavage into
subunits and processing, such as glycosylation, was likely
unchanged for the mutant protein.
Effectiveness of prophylaxis with palivizumab in cotton rats
Intramuscular prophylaxis with PZ was followed by RSV
challenge with either the A2 or MP4 viruses (Table 1).
Cotton rats administered PZ and challenged by A2 virus had
no virus detected in their lungs (group A), a greater than
99% reduction of lung RSV titers as compared with the PBS
prophylaxis control (group B). This was expected based on
earlier work (Johnson et al., 1997). However, PZ prophy-
laxis provided no protection against challenge by the MP4
virus (group C vs. D). Thus, the in vitro selected PZ
resistant virus MP4 was completely resistant to the prophy-
lactic effect of PZ in cotton rats.Discussion
The quasispecies nature of RNA viruses allows rapid
adaptation to changing selective pressures (Domingo and
Holland, 1994). Monoclonal and polyclonal antibody escape
mutants of RSV have been readily selected in cell culture
(Beeler and Van Wyke Coelingh, 1989; Crowe et al., 1998;
Garcia-Barreno et al., 1990; Lopez et al., 1990; Sullender and
Edwards, 1999; Walsh et al., 1998). There have been no
reports as to the capacity of such in vitro derived mutants to
escape antibody neutralization in vivo. MAb 1129 (the
murine parent to PZ) and PZ select for resistant viruses in
cell culture (Beeler and Van Wyke Coelingh, 1989; Johnson
et al., 1997). The MAb 1129 resistant virus also had reduced
susceptibility to neutralization by polyclonal hyperimmune
serum (Beeler andVanWykeCoelingh, 1989). Assessment of
PZ in cotton rats included testing for the presence of antibody
resistant viruses in the lungs after prophylaxis; apparently one
resistant virus was identified (Johnson et al., 1997).The murine parent of PZ, MAb 1129, was unable to
neutralize one of the clinical isolates against which it was
tested, indicating that circulating wild-type RSV may be
intrinsically resistant to PZ (Beeler and Van Wyke
Coelingh, 1989). A panel of RSV clinical isolates were
susceptible to neutralization by PZ at a concentration of
400 Ag/ml. Interestingly, 400 Ag/ml is 10-fold the target
concentration of 40 Ag/ml for prophylaxis and exceeds
the trough concentration of 72 Ag/ml reported after 4
months of prophylaxis (IMPACT, 1998; Johnson et al.,
1997).
How likely are PZ resistant viruses to arise? For other
short-lived infections such as influenza virus, antigenic
variants are thought to arise during serial transmission
through a partially immune population, providing a selec-
tive advantage for viruses that are able to evade host
immunity (Kilbourne, 1994; Webster, 1998). PZ is admin-
istered only to restricted populations and most RSV
infections do not occur among PZ recipients. Thus, it
seems unlikely there will be a selective advantage during
sequential passage through the general population. A
resistant virus might have a selective advantage during
transmission through several human hosts if resistance to
PZ is associated with reduced susceptibility to serum
antibodies as described for the MAb 1129 mutant (Beeler
and Van Wyke Coelingh, 1989). Further limiting the
likelihood of spread of resistant virus is that for children
with intact immune systems, the virus should be eradicated
by cellular immune responses even if the virus evades PZ.
The use of PZ in the profoundly immunocompromised,
such SCT patients, may provide a greater opportunity for
the emergence of resistant viruses. Cellular immunity is
critical for clearance of established RSV infections, and
patients who lack cellular immunity replicate RSV for
extended periods (Hall et al., 1986). PZ administered to
these patients may result in a situation of prolonged RSV
replication in the presence of antibody. Prolonged repli-
cation provides a longer period of selective pressure to
foster the emergence of PZ resistant viruses. RSV repli-
cation also can be prolonged in immunocompetent chil-
dren, with virus recovery for as long as 3 weeks (Hall et
al., 1976).
Selection of viral escape mutants has been described
after active and passive immunization in animal and
human populations, primarily under research conditions.
Influenza virus and foot-and-mouth disease virus (FMDV)
variants arise during passage of virus through immunized
mice (influenza virus) and cattle (FMDV) (Hamre et al.,
1958; Hyslop and Fagg, 1965). Vaccination of cattle
against FMDV with synthetic peptides rapidly selected
for FMDV antigenic variants (Taboga et al., 1997).
Human immunodeficiency virus type 1 variants arose in
a gp-120 vaccinated chimpanzee; the variants are resistant
to neutralization by early serum samples (Nara et al.,
1990). Hepatitis B virus (HBV) variants arise in humans
after active immunization and in liver transplant patients
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clinical care (Carman et al., 1990; Protzer-Knolle et al.,
1998). Thus, there is precedence for immunization to
result in the in vivo selection of escape mutants.
RSV is the only infectious disease for which a mono-
clonal antibody is commercially available for prophylaxis.
The increasingly wide spread use of PZ provides a unique
opportunity to consider the clinical implications and biol-
ogy of viruses that are resistant to antibody neutralization.
RSV quickly develops resistance to antibody neutralization
in vitro, and in other viral systems, immunization can
result in resistant viruses. Thus, it is possible for RSV to
develop resistance during PZ use. In addition, a wild-type
virus showed resistance to the PZ parent MAb 1129. The
work described here indicates that if such variants are
encountered, they could be completely resistant to the
beneficial effects of PZ prophylaxis. Monitoring for clin-
ical failures of PZ and surveillance for circulation of PZ
resistant viruses should reveal if clinically significant
mutants arise. Clinical failure of prophylaxis or PZ resis-
tant viruses has not been reported during post marketing
surveillance (Groothuis and Nishida, 2002). PZ is of
primary importance because of its use as a prophylactic
agent in humans. However, PZ use also offers opportuni-
ties to gain new insights into the transmission dynamics
and the quasispecies nature of RSV.Materials and Methods
Mutant selection
Palivizumab was purchased from a hospital pharmacy
(Synagis, Medimmune, Inc.). A2 virus (1  105 PFU)
was mixed with PZ (final concentration, 4 Ag/ml) and
guinea pig complement (final concentration 5%) at 37 jC
for 1 h to allow neutralization of susceptible virus (Sullen-
der and Edwards, 1999). Neutralized virus was inoculated
onto HEp-2 cells and grown in the presence of PZ (Table
1). Viral CPE was evident within 3–4 days and a virus-
containing cell suspension was harvested and clarified for
the next pass. After the first two passes, the neutralization
step was omitted. This process was repeated until pass 5
viral CPE was evident in 40 Ag/ml PZ. A mutant (MP4)
was obtained by plaque pick and used to produce viral
stocks for subsequent studies.
Microneutralization assay
The assay was performed as described previously with
slight modifications (Anderson et al., 1985). One thousand
PFU of A2 or MP4 virus was incubated with serially
diluted PZ in the presence of guinea pig complement for 1
h at 37 jC. These neutralized viral solutions were used to
inoculate HEp-2 cells in triplicate in 96-well plate for 1 h at
37 jC. After 3 days of incubation, the cells were fixedwith acetone. The amount of viral antigen present, mea-
sured using a G-protein-specific ELISA, was used as a
measure of viral replication. Mean absorbance at 450 nm
was recorded for triplicate wells.
F gene sequencing
RNA from A2 or MP4-infected HEp-2 cells was
extracted, and the F gene was amplified by RT-PCR
with primers F for (5V-cggggtaccGGGGCAAATAA-
CAATGGAGTTGC-3V), corresponding to genome nucleo-
tides 5601–5623 and nucleotides (lower case) that
include restriction site KpnI, and Frev (5V-cgcggatccCA-
GATGGTAAGTTAATCTGGC-3V), which complements
genome nucleotides 7515–7535 and nucleotides (lower
case) that include restriction site BamHI. PCR products
were purified by agarose gel electrophoresis and DNA
extraction (QIA Quick Gel Exraction Kit, Qiagen). Se-
quence determinations were done directly from the bulk
PCR products on an automated sequencing machine (ABI
Model 377 or 3100) at the UAB CFAR DNA sequencing
core facility.
Growth kinetics of A2 and MP4 in HEp-2 cells
HEp-2 cells in a 6-well plate were inoculated with
same amount of A2 or MP4 virus. One milliliter of virus-
containing media was harvested every 24 h. Viral titers
were determined by plaque assay on Vero cells.
Immunoblotting
Immunoblots were performed as described (Sullender,
1995). The proteins in cell lysates were separated by
electrophoresis on SDS–polyacrylamide gels and trans-
ferred to polyvinylidene fluoride membranes. The mem-
brane was incubated sequentially in a blocking solution,
diluted primary antibody, peroxidase-conjugated secondary
antibody, and finally in a chemiluminescent reagent and
exposed to radiographic film.
Prophylaxis in cotton rats
Cotton rats (Sigmodon hispidus) were obtained com-
mercially (Harlan, Indianapolis). Prophylaxis and control
groups were administered 15 mg/kg palivizumab (or a
similar volume of PBS for the control groups) intramus-
cularly 1 day before virus inoculation (IMPACT, 1998).
Cotton rats under ketamine/xylazine anesthesia were in-
oculated intranasally with 100 Al of RSV suspension
containing 5  105 plaque-forming units (PFU) of A2
or MP4 viruses. After 4 days, the animals were sacrificed
by carbon dioxide intoxication and lungs were obtained
for virus titration. Virus titers were determined by plaque
assay on Vero cells and expressed as plaque-forming unit
per gram of lung tissue.
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